Cargando…
Overcoming Drug Resistance and Treating Advanced Prostate Cancer
Most of the prostate cancers (PCa) in advanced stage will progress to castration-resistant prostate cancer (CRPC). Within CRPC group, 50-70% of the patients will develop bone metastasis in axial and other regions of the skeleton. Once PCa cells spread to the bone, currently, no treatment regimens ar...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474961/ https://www.ncbi.nlm.nih.gov/pubmed/22746994 http://dx.doi.org/10.2174/138945012802429615 |
_version_ | 1782246869595848704 |
---|---|
author | Semenas, Julius Allegrucci, Cinzia Boorjian, Stephen A Mongan, Nigel P Persson, Jenny Liao |
author_facet | Semenas, Julius Allegrucci, Cinzia Boorjian, Stephen A Mongan, Nigel P Persson, Jenny Liao |
author_sort | Semenas, Julius |
collection | PubMed |
description | Most of the prostate cancers (PCa) in advanced stage will progress to castration-resistant prostate cancer (CRPC). Within CRPC group, 50-70% of the patients will develop bone metastasis in axial and other regions of the skeleton. Once PCa cells spread to the bone, currently, no treatment regimens are available to eradicate the metastasis, and cancer-related death becomes inevitable. In 2012, it is estimated that there will be 28,170 PCa deaths in the United States. Thus, PCa bone metastasis-associated clinical complications and treatment resistance pose major clinical challenges. In this review, we will present recent findings on the molecular and cellular pathways that are responsible for bone metastasis of PCa. We will address several novel mechanisms with a focus on the role of bone and bone marrow microenvironment in promoting PCa metastasis, and will further discuss why prostate cancer cells preferentially metastasize to the bone. Additionally, we will discuss novel roles of several key pathways, including angiogenesis and extracellular matrix remodeling in bone marrow and stem cell niches with their relationship to PCa bone metastasis and poor treatment response. We will evaluate how various chemotherapeutic drugs and radiation therapies may allow aggressive PCa cells to gain advantageous mutations leading to increased survival and rendering the cancer cells to become resistant to treatment. The novel concept relating several key survival and invasion signaling pathways to stem cell niches and treatment resistance will be reviewed. Lastly, we will provide an update of several recently developed novel drug candidates that target metastatic cancer microenvironments or niches, and discuss the advantages and significance provided by such therapeutic approaches in pursuit of overcoming drug resistance and treating advanced PCa. |
format | Online Article Text |
id | pubmed-3474961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-34749612012-10-22 Overcoming Drug Resistance and Treating Advanced Prostate Cancer Semenas, Julius Allegrucci, Cinzia Boorjian, Stephen A Mongan, Nigel P Persson, Jenny Liao Curr Drug Targets Article Most of the prostate cancers (PCa) in advanced stage will progress to castration-resistant prostate cancer (CRPC). Within CRPC group, 50-70% of the patients will develop bone metastasis in axial and other regions of the skeleton. Once PCa cells spread to the bone, currently, no treatment regimens are available to eradicate the metastasis, and cancer-related death becomes inevitable. In 2012, it is estimated that there will be 28,170 PCa deaths in the United States. Thus, PCa bone metastasis-associated clinical complications and treatment resistance pose major clinical challenges. In this review, we will present recent findings on the molecular and cellular pathways that are responsible for bone metastasis of PCa. We will address several novel mechanisms with a focus on the role of bone and bone marrow microenvironment in promoting PCa metastasis, and will further discuss why prostate cancer cells preferentially metastasize to the bone. Additionally, we will discuss novel roles of several key pathways, including angiogenesis and extracellular matrix remodeling in bone marrow and stem cell niches with their relationship to PCa bone metastasis and poor treatment response. We will evaluate how various chemotherapeutic drugs and radiation therapies may allow aggressive PCa cells to gain advantageous mutations leading to increased survival and rendering the cancer cells to become resistant to treatment. The novel concept relating several key survival and invasion signaling pathways to stem cell niches and treatment resistance will be reviewed. Lastly, we will provide an update of several recently developed novel drug candidates that target metastatic cancer microenvironments or niches, and discuss the advantages and significance provided by such therapeutic approaches in pursuit of overcoming drug resistance and treating advanced PCa. Bentham Science Publishers 2012-09 2012-09 /pmc/articles/PMC3474961/ /pubmed/22746994 http://dx.doi.org/10.2174/138945012802429615 Text en © 2012 Bentham Science Publishers http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Semenas, Julius Allegrucci, Cinzia Boorjian, Stephen A Mongan, Nigel P Persson, Jenny Liao Overcoming Drug Resistance and Treating Advanced Prostate Cancer |
title | Overcoming Drug Resistance and Treating Advanced Prostate Cancer |
title_full | Overcoming Drug Resistance and Treating Advanced Prostate Cancer |
title_fullStr | Overcoming Drug Resistance and Treating Advanced Prostate Cancer |
title_full_unstemmed | Overcoming Drug Resistance and Treating Advanced Prostate Cancer |
title_short | Overcoming Drug Resistance and Treating Advanced Prostate Cancer |
title_sort | overcoming drug resistance and treating advanced prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474961/ https://www.ncbi.nlm.nih.gov/pubmed/22746994 http://dx.doi.org/10.2174/138945012802429615 |
work_keys_str_mv | AT semenasjulius overcomingdrugresistanceandtreatingadvancedprostatecancer AT allegruccicinzia overcomingdrugresistanceandtreatingadvancedprostatecancer AT boorjianstephena overcomingdrugresistanceandtreatingadvancedprostatecancer AT mongannigelp overcomingdrugresistanceandtreatingadvancedprostatecancer AT perssonjennyliao overcomingdrugresistanceandtreatingadvancedprostatecancer |